Neoantigen Cancer Vaccine Market 2026-2034 | Size, Trends & Opportunities

The global neoantigen cancer vaccine market is projected to grow from approximately US$ 495.05 million in 2025 to about US$ 1887.25 million by 2034, registering a CAGR of 16.03% during 2026‑2034.

Neoantigen Cancer Market Analysis

The neoantigen cancer vaccine market is being driven by several key factors, including the rising global burden of cancer and the shift toward personalized immunotherapies targeting tumor‑specific mutations. Technological enablers such as next‑generation sequencing, bioinformatics, and artificial intelligence for neoantigen prediction are accelerating the development of bespoke vaccines.

Furthermore, the ability to integrate neoantigen vaccines with immunotherapy regimens (e.g., checkpoint inhibitors) is broadening the therapeutic scope. Challenges remain, such as manufacturing complexity, regulatory pathways for individualized therapies, and demonstrating long‑term clinical benefit across diverse tumor types.

Neoantigen Cancer Market Overview

Neoantigen cancer vaccines are immunotherapies designed to elicit an immune response against tumor‑specific neoantigens, mutated proteins present only on cancer cells. These vaccines aim to stimulate T‑cells to recognize and eliminate malignant cells while sparing normal tissue.

In practice, the development workflow involves tumor biopsy, sequencing, neoantigen identification, vaccine manufacturing (e.g., mRNA, peptide, dendritic‑cell formats), and administration, often in combination with other immunotherapies. The market encompasses personalized (patient‑specific) and off‑the‑shelf neoantigen vaccines, with varied delivery platforms and end‑user settings.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Neoantigen Cancer Vaccine Market: Strategic Insights

Neoantigen Cancer Drivers and Opportunities

Market Drivers:

• Rising incidence of cancer globally and demand for more effective, targeted immunotherapies.
• Advances in sequencing, bioinformatics, and AI are enabling faster neoantigen discovery and vaccine development.
• Growing partnerships between biotech/pharma and academia for neoantigen vaccine pipelines and combinations with checkpoint inhibitors.

Market Opportunities:

• Expansion of off‑the‑shelf neoantigen vaccine platforms to improve scalability and cost‑effectiveness.
• Emerging markets (such as Asia‑Pacific and other regions) with seeing oncology infrastructure and increasing adoption of precision medicine.
• Integration of neoantigen vaccines with other modalities (e.g., cell therapies, checkpoint inhibitors) and leveraging AI/ML for enhanced epitope prediction and vaccine design.

Neoantigen Cancer Report Segmentation Analysis

The market is commonly segmented using the following taxonomy:

By Product:

• Personalized neoantigen vaccines (patient‑specific)
• Off‑the‑shelf neoantigen vaccines

By Neoantigen Source/Type:

• Neoantigens derived from tumor mutations
• Shared neoantigens / common tumor antigens

By Vaccine Platform / Technology:

• Peptide‑based
• Nucleic acid (DNA/RNA) ‑based.
• Dendritic‑cell / cell‑based

By Administration / Delivery Mode:

• Intravenous
• Intramuscular
• Other routes (e.g., intradermal)

By End‑Use Industry / Application:

• Hospitals & clinics
• Specialized cancer treatment centers
• Academic & research institutions

By Geography:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Neoantigen Cancer Vaccine Market Regional Insights

The regional trends and factors influencing the Neoantigen Cancer Vaccine Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Neoantigen Cancer Vaccine Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Neoantigen Cancer Vaccine Market Report Scope

Neoantigen Cancer Vaccine Market Players Density: Understanding Its Impact on Business Dynamics

The Neoantigen Cancer Vaccine Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Neoantigen Cancer Market Share Analysis by Geography

• North America leads the market, driven by advanced oncology infrastructure, high adoption of personalized immunotherapies, and significant R&D investment.
• Europe is a strong region with robust academic‑industry collaborations and favorable regulatory initiatives for personalized therapies.
• Asia Pacific is one of the fastest‑growing markets, with rising healthcare expenditures, growing cancer burden, and increasing precision medicine adoption.

Emerging regions in Latin America, the Middle East & Africa present untapped opportunities, though currently smaller in share due to infrastructure and reimbursement challenges.

Neoantigen Cancer Market Players Density: Understanding Its Impact on Business Dynamics

The neoantigen cancer vaccine market features a mix of large biopharma and biotechnology companies, academic consortia, and niche players. This results in a densely competitive landscape with continuous innovation.

Key competitive strategies include:

• Rapid neoantigen discovery and vaccine manufacturing turnaround
• Leveraging AI and genomics for predictive accuracy
• Collaborations/licensing with academic centers and major oncology players
• Scaling personalized therapies into broader patient populations via off‑the‑shelf platforms

Major Companies operating in the Neoantigen Cancer Vaccine Market

1. Moderna, Inc.
2. BioNTech SE
3. Merck & Co., Inc.
4. F. Hoffmann‑La Roche Ltd
5. Gritstone Bio, Inc.
6. Agenus Inc.
7. OSE Immunotherapeutics SA
8. Advaxis, Inc.
9. Medigene AG
10. Genocea Biosciences, Inc.

Other companies analyzed during the course of research:

1. Neon Therapeutics, Inc.
2. Vaccibody AS
3. BrightPath Biotherapeutics Co. Ltd
4. Novogene Co. Ltd
5. Immunovative Therapies Ltd.
6. Frame Therapeutics GmbH

Neoantigen Cancer Market News and Recent Developments

• The neoantigens market is projected to reach USD 10.55 billion by 2028 with a CAGR of 31.2%, highlighting the growing impact of AI in neoantigen vaccine development.
• A new industry report indicates the global neoantigen cancer vaccine market grew from approximately USD 378.66 million in 2024 to USD 434.55 million in 2025, and is expected to reach USD 876.78 million by 2030 at a CAGR of ~15.0%.
• Recent published research underscores the increased use of personalized neoantigen vaccine platforms, with updated trial data highlighting T‑cell responses in patients across tumor types.

Neoantigen Cancer Market Report Coverage and Deliverables

The report “Neoantigens Market Forecast to 2028 – COVID‑19 Impact and Global Analysis by Treatment and Therapeutic Specialty” from The Insight Partners provides:

• Size and forecast of the neoantigen cancer vaccine market at the global, regional, and country levels for all key segments
• Trends, drivers, restraints, and key opportunities in the market
• Detailed PEST and SWOT analyses
• Market analysis covering key market trends, global and regional frameworks, major players, key regulations, and recent developments
• Industry landscape and competition analysis, including market concentration, heat map, prominent players, and recent developments
• Detailed company profiles